Nephrotoxicity of cisplatin and carboplatin in sarcoma patients: A report from the late effects surveillance system

Pediatric Blood and Cancer

Volumn 48, Issue 2, 2007, Pages 140-147

  Stohr W ^a   Paulides, M ^a   Bielack, S ^b,c   Jurgens H ^b   Koscielniak, E ^d   Rossi, R ^e   Langer, T ^a   Beck, J D ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^c OLGAHOSPITAL   (Germany)

^d Hematology   (Germany)

^e VIVANTES KLINIKUM NEUKÖLLN   (Germany)

Author keywords

Cancer; Carboplatin; Children; Cisplatin; Hypomagnesemia; Nephrotoxicity

Indexed keywords

BUSULFAN; CARBOPLATIN; CISPLATIN; CREATININE; DACTINOMYCIN; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; IFOSFAMIDE; MAGNESIUM; MELPHALAN; METHOTREXATE; VINCRISTINE;

ADOLESCENT; ARTICLE; CANCER RADIOTHERAPY; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG SURVEILLANCE PROGRAM; EWING SARCOMA; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; HYPOMAGNESEMIA; LONGITUDINAL STUDY; MAGNESIUM BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; OSTEOSARCOMA; PRIORITY JOURNAL; PROSPECTIVE STUDY; SARCOMA; SOFT TISSUE SARCOMA; STATISTICAL ANALYSIS;

ADOLESCENT; ANTINEOPLASTIC AGENTS; CARBOPLATIN; CHILD; CHILD, PRESCHOOL; CISPLATIN; CREATININE; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; IFOSFAMIDE; KIDNEY; LONGITUDINAL STUDIES; MAGNESIUM; MALE; PROSPECTIVE STUDIES; SARCOMA;

EID: 33845660889     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.20812     Document Type: Article

References (48)

1. Ariceta G, Rodriguez-Soriano J, Vallo A, et al. Acute and chronic effects of cisplatin therapy on renal magnesium homeostasis. Med Pediatr Oncol 1997;28:35-40.
2. Brillet G, Deray G, Jacquiaud C, et al. Long-term renal effect of cisplatin in man. Am J Nephrol 1994;14:81-84.
3. Brock PR, Koliouskas DE, Barratt TM, et al. Partial reversibility of cisplatin nephrotoxicity in children. J Pediatr 1991;118:531-534.
4. Jaffe N, Keifer R III, Robertson R, et al. Renal toxicity with cumulative doses of cis-diamminedichloroplatinum-ii in pediatric patients with osteosarcoma. Effect on creatinine clearance and methotrexate excretion. Cancer 1987;59:1577-1581.
5. Skinner R, Pearson AD, English MW, et al. Cisplatin dose rate as a risk factor for nephrotoxicity in children. Br J Cancer 1998;77: 1677-1682.
6. Von der Weid NX, Erni BM, Mamie C, et al. Cisplatin therapy in childhood: Renal follow up 3 years or more after treatment. Swiss Pediatric Oncology Group. Nephrol Dial Transplant 1999;14: 1441-1444.
7. Womer RB, Pritchard J, Barratt TM. Renal toxicity of cisplatin in children. J Pediatr 1985;106:659-663.
8. Lajer H, Daugaard G. Cisplatin and hypomagnesemia. Cancer Treat Rev 1999;25:47-58.
9. Pinzani V, Bressolle F, Haug IJ, et al. Cisplatin-induced renal toxicity and toxicity-modulating strategies: A review. Cancer Chemother Pharmacol 1994;35:1-9.
10. Erdlenbruch B, Pekrum A, Roth C, et al. Cisplatin nephrotoxicity in children after continuous 72-h and 3x1-h infusions. Pediatr Nephrol 2001;16:586-593.
11. Stewart DJ, Dulberg CS, Mikhael NZ, et al. Association of cisplatin nephrotoxicity with patient characteristics and cisplatin administration methods. Cancer Chemother Pharmacol 1997;40:293-308.
12. Bianchetti MG, Kanaka C, Ridolfi-Luthy A, et al. Chronic renal magnesium loss, hypocalciuria and mild hypokalaemic metabolic alkalosis after cisplatin. Pediatr Nephrol 1990;4:219-222.
13. Koch Nogueira PC, Hadj-Aissa A, Schell M, et al. Long-term nephrotoxicity of cisplatin, ifosfamide, and methotrexate in osteosarcoma. Pediatr Nephrol 1998;12:572-575.
14. Goren MP. Cisplatin nephrotoxicity affects magnesium and calcium metabolism. Med Pediatr Oncol 2003;41:186-189.
15. English MW, Skinner R, Pearson AD, et al. Dose-related nephrotoxicity of carboplatin in children. Br J Cancer 1999;81: 336-341.
16. Brandt LJ, Broadbent V. Nephrotoxicity following carboplatin use in children: Is routine monitoring of renal function necessary? Med Pediatr Oncol 1993;21:31-35.
17. Castello MA, Clerico A, Jenkner A, et al. A pilot study of high-dose carboplatin and pulsed etoposide in the treatment of childhood solid tumors. Pediatr Hematol Oncol 1990;7:129-135.
18. Ettinger LJ, Gaynon PS, Krailo MD, et al. A phase II study of carboplatin in children with recurrent or progressive solid tumors. A report from the childrens cancer group. Cancer 1994;73:1297-1301.
19. Pinkerton CR, Broadbent V, Horwich A, et al. 'JEB'-a carboplatin based regimen for malignant germ cell tumours in children. Br J Cancer 1990;62:257-262.
20. Stevens MC, Lewis IJ, Pearson AJ, et al. Carboplatin and renal function in children. Br J Cancer 1991;63:158.
21. Kintzel PE. Anticancer drug-induced kidney disorders. Drug Saf 2001;24:19-38.
22. Beyer J, Rick O, Weinknecht S, et al. Nephrotoxicity after high-dose carboplatin, etoposide and ifosfamide in germ-cell tumors: Incidence and implications for hematologic recovery and clinical outcome. Bone Marrow Transplant 1997;20:813-819.
23. Frenkel J, Kool G, de Kraker J. Acute renal failure in high dose carboplatin chemotherapy. Med Pediatr Oncol 1995;25:473-474.
24. Langer T, Henze G, Beck J. Basic methods and the developing structures of a late effects surveillance system (LESS) in the long-term follow-up of pediatric cancer patients in Germany. Med Pediatr Oncol 2000;34:348-351.
25. Langer T, Stohr W, Bielack S, et al. Late effects surveillance system for sarcoma patients. Pediatr Blood Cancer 2004;42:373-379.
26. Langer T, Stohr W, Paulides M, et al. Prospective multicenter registration of major late sequelae in sarcoma patients using the late effects surveillance system (LESS). Klin Padiatr 2005;217:176-181.
27. Schwartz GJ, Brion LP, Spitzer A. The use of plasma creatinine concentration for estimating glomerular filtration rate in infants, children, and adolescents. Pediatr Clin North Am 1987;34:571-590.
28. Thomas L. Labor und Diagnose. Frankfurt/Main: TH-Books Verlagsgesellschaft mbH; 2000.
29. Zuppinger K. Berner Datenbuch der Pädiatrie. München: Urban & Fischer; 1992.
30. DCTD, NCI, NIH, et al. Cancer therapy evaluation program, common terminology criteria for adverse events version 3.0. http://ctepcancergov 2003.
31. Schilsky RL, Barlock A, Ozols RF. Persistent hypomagnesemia following cisplatin chemotherapy for testicular cancer. Cancer Treat Rep 1982;66:1767-1769.
32. Skinner R, Parry A, Price L, et al. Ten year follow-up of renal function after ifosfamide or platinum treatment. Pediatr Blood Cancer 2005;45:554-555.
33. Bell DR, Woods RL, Levi JA. Cis-diamminedichloroplatinum-induced hypomagnesemia and renal magnesium wasting. Eur J Cancer Clin Oncol 1985;21:287-290.
34. Daugaard G, Strandgaard S, Holstein-Rathlou NH, et al. The renal handling of sodium and water is not affected by the standard-dose cisplatin treatment for testicular cancer. Scand J Clin Lab Invest 1987;47:455-459.
35. Rude RK, Kirchen ME, Gruber HE, et al. Magnesium deficiency-induced osteoporosis in the rat: Uncoupling of bone formation and bone resorption. Magnes Res 1999;12:257-267.
36. Toba Y, Kajita Y, Masuyama R, et al. Dietary magnesium supplementation affects bone metabolism and dynamic strength of bone in ovariectomized rats. J Nutr 2000;130:216-220.
37. Dentino M, Luft FC, Yum MN, et al. Long term effect of cis-diamminedichloride platinum (CDDP) on renal function and structure in man. Cancer 1978;41:1274-1281.
38. Fjeldborg P, Sorensen J, Helkjaer PE. The long-term effect of cisplatin on renal function. Cancer 1986;58:2214-2217.
39. Hamilton CR, Bliss JM, Horwich A. The late effects of cis-platinum on renal function. Eur J Cancer Clin Oncol 1989;25:185-189.
40. MacLeod PM, Tyrell CJ, Keeling DH. The effect of cisplatin on renal function in patients with testicular tumours. Clin Radiol 1988;39:190-192.
41. Springate JE, Christensen SL, Feld LG. Serum creatinine level and renal function in children. Am J Dis Child 1992;146:1232-1235.
42. Schwartz GJ, Haycock GB, Edelmann CM Jr., et al. A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine. Pediatrics 1976;58:259-263.
43. Haycock GB. Creatinine, body size and renal function. Pediatr Nephrol 1989;3:22-24.
44. Seikaly MG, Browne R, Bajaj G, et al. Limitations to body length/serum creatinine ratio as an estimate of glomerular filtration in children. Pediatr Nephrol 1996;10:709-711.
45. Skinner R, Cole M, Pearson AD, et al. Inaccuracy of glomerular filtration rate estimation from height/plasma creatinine ratio. Arch Dis Child 1994;70:387-390.
46. Haim N, Oman SD, Galai N, et al. Estimation of creatinine clearance without 24-hour urine collection-a useful guide during cisplatin therapy. Acta Oncol 1993;32:409-412.
47. Rossi R, Godde A, Kleinebrand A, et al. Unilateral nephrectomy and cisplatin as risk factors of ifosfamide- induced nephrotoxicity: Analysis of 120 patients. J Clin Oncol 1994;12:159-165.
48. Goren MP, Wright RK, Horowitz ME. Cumulative renal tubular damage associated with cisplatin nephrotoxicity. Cancer Chemother Pharmacol 1986;18:69-73.